Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review.
-
アブストラクト Gemtuzumab ozogamicin (GO) is a CD33 monoclonal antibody-drug conjugate currently in use to treat myeloid malignancies. A unique adverse effect of this medication is destruction of CD33 positive macrophages resulting in reduced clearance of free hemoglobin leading to grossly red plasma. This build-up of free hemoglobin can potentially lead to end organ damage and prevent performance of clinically necessary laboratory evaluation. We present a case of a pediatric patient who developed this adverse effect and was successfully treated with therapeutic plasma exchange (TPE). We also present results from a systematic review of the medical literature and share data from a query of the United States Food and Drug Administration (FDA) Adverse Event Reporting system for GO-related hemoglobin scavenging impairment. Among reported cases, patients undergoing TPE and those receiving steroids had improved outcomes. Practitioners should be aware of this rare drug side-effect and the potential utility of TPE for these patients. ジャーナル名 Journal of clinical apheresis Pubmed追加日 2024/4/22 投稿者 Adkins, Brian D; Noland, Daniel K; Slone, Tamra; Sadanand, Arhanti 組織名 Department of Pathology, University of Texas Southwestern Medical Center, Dallas,;Texas, USA.;Children's Health System, Dallas, Texas, USA.;Division of Hematology and Oncology, Department of Pediatrics, University of;Texas Southwestern Medical Center, Dallas, Texas, USA. Pubmed リンク https://www.ncbi.nlm.nih.gov/pubmed/38647036/ -
お問合わせ
検索
メルマガ登録
